About: Julien Taïeb

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Julien Taïeb Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	forskare (sv) researcher (en) 연구원 (ko) 研究者 (ja) araştırmacı (tr) дослідник (uk) эрдэмтэн (mn) изилдөөчү (ky) 研究者 (zh) onderzoeker (nl)
rdfs:label	Julien Taïeb (en) Julien Taïeb (es) Julien Taïeb (fr) Julien Taïeb (it) Julien Taïeb (sl) Julien Taïeb (ast)
skos:prefLabel	Julien Taïeb (en) Julien Taïeb (es) Julien Taïeb (fr) Julien Taïeb (it) Julien Taïeb (sl) Julien Taïeb (ast)
name	Julien Taïeb (en) Julien Taïeb (es) Julien Taïeb (fr) Julien Taïeb (it) Julien Taïeb (sl) Julien Taïeb (ast)
LinkedIn personal profile ID	wds:Q41784351-31E9A101-0B34-46E7-B86B-378D4AFAB60A
LinkedIn personal profile ID	julien-taieb-7781a43
given name	wds:Q41784351-62C6ED7D-9812-4483-A9EF-9855EECB72A1
given name	Julien
instance of	wds:Q41784351-C9FF3E6C-D82E-489C-908A-E42DDEED8CED
instance of	Homo sapiens
Google Scholar author ID	wds:Q41784351-61a0d9c4-4467-62bc-5f50-b13e8d315fc2
Google Scholar author ID	niwd5qgAAAAJ
Theses.fr person ID	wds:Q41784351-ba2d5c5f-4475-cd32-75ef-e32648f711fb
Theses.fr person ID	http://www.theses.fr/141901977/id
Theses.fr person ID	141901977
occupation	wds:Q41784351-8D2E1872-FA66-4428-820A-171B426BD913
languages spoken, written or signed	wds:Q41784351-EF81C67C-7D55-4F37-B21B-418F13D4067E
sex or gender	wds:Q41784351-9C8DE141-4B02-4D99-B494-B0DD476F1A57
ISNI	wds:Q41784351-C12172E1-A92E-4A0D-B630-2C6C506FB72B
VIAF ID	wds:Q41784351-A5F3A5A2-6D1F-4485-9D95-2C8EDC1B9DAE
Bibliothèque nationale de France ID	wds:Q41784351-BD78C8D1-4655-4BC9-90C9-AE2E588C406C
IdRef ID	wds:Q41784351-5B2A8FA6-2760-4BD5-BB5B-8F16CE0CF565
date of birth	wds:Q41784351-dd4baac2-47ff-ac47-1aa8-4adccac057b9
WorldCat Identities ID (superseded)	wds:Q41784351-1AFB2BEF-A7E4-431C-B9CD-177EE3C8E2F0
VIAF ID	http://viaf.org/viaf/15706613
Bibliothèque nationale de France ID	http://data.bnf.fr/ark:/12148/cb162149469#about
IdRef ID	http://www.idref.fr/141901977/id
occupation	researcher
languages spoken, written or signed	French
sex or gender	male
ISNI	0000000433518594
VIAF ID	15706613
Bibliothèque nationale de France ID	162149469
IdRef ID	141901977
date of birth	1969-01-01 00:00:00Z (xsd:dateTime)
WorldCat Identities ID (superseded)	viaf-15706613
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q41784351
is author of	Dendritic cell-derived exosomes as cell-free peptide-based vaccines Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha Modulation of immunity by antiangiogenic molecules in cancer Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects A novel dendritic cell subset involved in tumor immunosurveillance Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer Control of the immune response by pro-angiogenic factors VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner The potential of exosomes in immunotherapy of cancer Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. Hepatocellular carcinoma (HCC): an update Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial 5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer Dendritic cell derived-exosomes: biology and clinical implementations Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer The potential of exosomes in immunotherapy Checkpoint inhibitors and gastrointestinal immune-related adverse events Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software